Foresite Capital Explained

Foresite Capital
Type:Private company
Industry:Venture capital, growth equity
Founder:Jim Tananbaum
Area Served:Worldwide
Key People:Jim Tananbaum (CEO)
Hq Location City:San Francisco
Hq Location Country:United States

Foresite Capital (Foresite) is an American, multi-stage healthcare and life sciences investment firm headquartered in Los Angeles, and with offices in The San Francisco Bay Area and New York City.[1] [2] As of June 2024, the company had raised six primary funds: Foresite Capital Fund I, II, III, IV, V and VI.[1] [3]

History

Foresite Capital was founded in 2011 by Jim Tananbaum.[4] [5] [6] Foresite Capital raised its $100 million Fund I in 2013.[7] [8] [6] In 2014, Foresite Capital closed Foresite Capital Fund II, a $300 million fund. Foresite Capital Fund III, a $450 million fund, was closed in July 2015.[9] Foresite Capital Fund IV, a $668 million fund, closed in March 2018.[10] Foresite Capital Fund V, a $776 million fund and its associated opportunity fund closed in February 2021.[11] Foresite Labs Fund I, a $173 million fund, closed in January 2022. Foresite Capital Fund VI, a $900 million fund, closed in May 2024.[12]

Investments

Foresite Capital funded 10x Genomics since its Series A round in November 2013 and led its Series B round in January 2015, as well as its Series C round in March 2016.[13] [14] Foresite Capital has invested in companies such as Acceleron Pharma, Aimmune, Alumis, ALX Oncology, Aerie Pharmaceuticals,[15] Ascendis, Blueprint Medicines, CG Oncology, Color Genomics, Cue Health, Cytokinetics, DNAnexus, Editas Medicine,[16] Eikon Therapeutics, Element Biosciences,[17] Epizyme,[1] Evonetix, Intarcia Therapeutics,[18] [19] Inscripta,[20] Immunomedics,[21] [22] Intellia Therapeutics, Juno Therapeutics,[23] Karyopharm, Keryx, Kura Oncology, Keros Therapeutics, Latigo, Maze Therapeutics, MyoKardia, MyOme, Natera, Nurix, Olema Oncology, Orexigen,[24] Pacific Biosciences,[25] Peloton Therapeutics, Pharvaris, MindStrong Health, Quantum-SI, Relay Therapeutics,[26] Insitro,[27] HealthVerity, Turning Point Therapeutics, Portola Pharmaceuticals, Universal American, Xaira Therapeutics, Xencor, RayThera, and WaveTech, in addition to 10x Genomics.[28]

Leadership

Foresite Capital is led by Midas List honoree Jim Tananbaum along with managing directors Vikram Bajaj,[29] Dorothy Margolskee, Michael Rome, Dennis Ryan, and Hadi Tabbaa.[30] [31]

Notes and References

  1. News: Foresite Capital Keeps Late-Stage Healthcare Focus With $450M Third Fund. David Holley. 29 July 2015. Xconomy. 20 May 2017.
  2. News: Growth-Equity Firm Foresite Capital Raises $100M for Debut Health-Care Fund. Brian Gormley. 31 January 2013. Wall Street Journal. 20 May 2017.
  3. Web site: Foresite Capital launchew new venture capital fund worth $668 million. Biospace . 21 June 2019.
  4. News: Foresite Capital reloads with a $450M biotech venture fund. Damian Garde. 29 July 2015. Fierce Biotech. 20 May 2017.
  5. News: Foresite Capital raises $100M to invest in late-stage healthcare companies. 31 January 2013. San Francisco Business Times. 20 May 2017.
  6. News: Health care venture firm Foresite Capital closes $300M fund. Eric Blattberg. 1 April 2014. Venture Beat. 20 May 2017.
  7. News: Karyopharm Prices Upsized IPO at $16 Per Share, Begins Trading Today. Ben Fidler. 6 November 2013. Xconomy. 20 May 2017.
  8. News: Foresite Capital Closes $100M Fund for Late-Stage Biotechs. Luke Timmerman. 31 January 2013. Xconomy. 20 May 2017.
  9. News: Foresite banks $300M to bet on late-stage biotechs. Damian Gards. 1 April 2014. Fierce Biotech. 20 May 2017.
  10. Web site: Venture fund Foresite Capital raises largest-ever $668m fund . Mass Device . 4 May 2018 . 19 June 2019.
  11. Web site: Foresite Capital raises $969 million fund to invest in healthcare startups across all stages of growth. 2021-03-16. TechCrunch. en-US.
  12. Web site: VC's new $900 million fund looks to push tech-biotech innovation. The Business Journals . 12 June 2024.
  13. News: 10X Genomics scoops another $55M to fuel commercialization of long-read tech. Nick Paul Taylor. 21 March 2016. Fierce Biotech. 20 May 2017.
  14. News: 10X Genomics Emerges With $80M and Toaster-Sized Sequencer Upgrade. Alex Lash. 12 January 2015. Xconomy. 20 May 2017.
  15. News: Aerie Stock Hits Record High, Holder Sells $2 Million. Ed Lin. 14 October 2016. Barrons. 20 May 2017.
  16. Web site: Foresite Capital - Massinvestor Venture Capital and Private Equity Database. massinvestordatabase.com. 2019-02-27.
  17. Web site: Element Biosciences Lands $15M to Develop New Genetic Analysis Tools. Xconomy . 21 June 2019.
  18. News: Diabetes 'Unicorn' Raises Final VC Round Before IPO. Dan Primack. 15 September 2016. Fortune. 20 May 2017.
  19. News: Here's who stands to gain from Intarcia's success with a type 2 diabetes pump. 2 October 2014. Boston Business Journal. 20 May 2017.
  20. News: Muse Bio Closes $23M Series B Financing Round. Genome Web. 20 May 2017.
  21. Web site: FORESITE CAPITAL MANAGEMENT III, LLC Institutional Portfolio. NASDAQ.com. en-us. 2019-05-02.
  22. Web site: Intarcia Therapeutics Venture Capital and Private Equity Financings. www.vcnewsdaily.com. 2019-02-27.
  23. Web site: Foresite Capital reloads with a $450M biotech venture fund. FierceBiotech. en. 2019-05-02.
  24. Web site: Xconomy: Foresite Capital Reloads With New $300M Late-Stage Biotech Fund. 2014-04-01. Xconomy. en. 2019-05-14.
  25. Web site: Stealthy 10X Genomics Raises $55.5M To Beef Up DNA Sequencing. Timmerman. Luke. Forbes. en. 2019-05-14.
  26. Web site: Relay Therapeutics hits VC jackpot with $400M series C round for protein-motion drug discovery. Med City News . 20 December 2018 . 19 June 2019.
  27. Web site: Backed by big-name VCs, this startup is turning machine learning on drug discovery . The Business Journals . 19 June 2019.
  28. Web site: Foresite Capital Management Iv, Llc - Latest 13F Holdings - Fintel.io. fintel.io. en. 2019-05-14.
  29. Web site: Heir Apparent at Carnegie Corp. Exits for Biotech Venture Firm . Institutional Investor . 14 October 2020 . 18 December 2020.
  30. Web site: A life sciences firm run by a top VC and a cofounder of Alphabet's life sciences arm, just raised its biggest fund yet. TechCrunch . 5 May 2018 . 19 June 2019.
  31. Web site: Nine VCs who matter but you never read about. Knect365 . 19 June 2019.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Foresite Capital".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.